Treatment Update: Myelodysplastic Syndromes (MDS)

Поділитися
Вставка
  • Опубліковано 11 тра 2022
  • Topics Covered
    We invite you to learn more about:
    • Myelodysplastic syndromes subtypes
    • Current and emerging treatments
    • Side-effects management
    • The importance of communication with your healthcare team
    Speaker
    Mikkael A. Sekeres, MD
    Professor of Medicine
    Chief, Division of Hematology
    Sylvester Comprehensive Cancer Center
    University of Miami
    Miami, FL

КОМЕНТАРІ • 7

  • @philwhitcroft914
    @philwhitcroft914 26 днів тому

    Brilliant information many thanks for your help

  • @tazroni9100
    @tazroni9100 23 дні тому

    Thank you, i learn alot from this video.

  • @billygarner7362
    @billygarner7362 Рік тому +2

    When on Reblozyl toward the end of its course fatigue was constant. Also shortness of breath accompanied the low Hb. I am now on Azacitidine and have finished the third course. My Hb is up from 7-8 to near 11. The fatigue is improved and SOB has gone away. Side effects have been minimal, constipation being the main one. I hope for a long successful therapy. After it comes BMT. I’m not looking forward to that.

  • @Cincyseller513
    @Cincyseller513 Рік тому

    You are an amazing Dr. Thank you for all of this info providing the medical side with studies and acknowledging how our immune system can cure us and adding diet is important :)

  • @at6969
    @at6969 2 роки тому

    Excellent

  • @ronoconnor8971
    @ronoconnor8971 8 місяців тому

    Procrit weekly has my hgb to +10 but my dizziness and larthogy is very bad. Ive been anemic for many years and was diagnosed with mds last year

  • @Anti-leftist7777
    @Anti-leftist7777 8 місяців тому

    I have ASXL1, excess blasts @15%, low white blood cells, platelets at 10 up to 30 when I have transfusions twice a week. One cycle Vidaza completed with a few coming and a stem cell transplant in a couple months. Additionally multiple myeloma just diagnosed. Chances of success, years?
    The ASXL1 concerns me.